Seeking Synthetic Methods for Chemo- and Site-selective Bioconjugation in Proteins

Asahi Kasei Pharma, a global pharmaceutical company, is seeking chemical conjugation methods for N- or C-terminal specific protein modifications. In addition, the team is also interested in synthetic methods for chemo-selective and site-selective bioconjugation, including intermediate-site selective (e.g. Lysine- specific) bioconjugation.

Approaches of Interest:

• Ideally, submissions should include experimental data with the name of the model protein, reaction site and/or residue, conversion rate, and selectivity
• Methods that produce high protein yields are of highest interest and scaling up for GMP production should be possible
• Stable bond formation in buffered conditions 
• To improve selectivity and conversion, the method of traceless affinity compound is acceptable

Out of Scope:

• Uncontrolled reactions at multiple sites are out of scope 

Developmental Stages of Interest:

• Opportunities from basic research phase to Phase III are within scope, provided there is quantitative data using more than one model protein to confirm conversion rate, selectivity, and isolated yield

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Asahi Kasei Pharma has high interest biopharma technologies and is also open to hearing from CROs and CMOs. Additionally, novel research proposals are of interest and can be outlined using this submission form. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include technology licensing, project funding, and research collaborations.